Methods The single-arm, multicenter phase II study is ongoing and evaluating the efficacy
and safety of anlotinib plus pemetrexed plus cisplatin for first-line treatment of driver …

Background The advent of immunotherapy has revolutionized non-small cell lung cancer
(NSCLC) treatment. Anlotinib (AN), a multitargeted tyrosine kinase inhibitor, holds promise …

Methods This is a single-arm phase II trial, in which advanced NSCLC patients with
treatment failure of platinum-based doublet chemotherapy were enrolled and administrated …

Introduction Anlotinib has brought about marked progression-free survival and overall
survival benefit compared with placebos as third-line or further treatment in advanced …

Background Four multi-targeted tyrosine kinase inhibitors (TKIs) including apatinib,
anlotinib, fruquintinib and lenvatinib are currently available as third-line regimen for …

Background Given the synergy effect of immunotherapy and anti-angiogenic therapy in
advanced NSCLC, FDA approved atezolizumab plus bevacizumab and chemotherapy as …

Objective The purpose of this study was to initially investigate the effect of previous
antiangiogenic therapy (bevacizumab and endostatin) on the efficacy of anlotinib in patients …

Background: Anlotinib, an oral multi-targeted tyrosine kinase receptor inhibitor, monotherapy
improves OS and PFS as a third-line treatment for stage IV NSCLC. Bevacizumab added to …

Despite the wide clinical application of immune checkpoint inhibitors (ICIs) monotherapy in
advanced non-small-cell lung cancer (NSCLC), the limited benefit rate still puzzles …

Background Docetaxel is one of the standard second-line therapies for non-small cell lung
cancer (NSCLC), but the clinical outcomes are poor. Anlotinib, a novel anti-angiogenesis …